Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.


Related Content

Sanofi Working To Resolve GMP Issues That Derailed Sarilumab Approval
Merck’s C. Diff Drug Zinplava Clears FDA With Heart Failure Warning
Merck Says PD-L1 Testing Already On The Rise, Setting Stage For First-Line Launch
FDA Continues To Speed PD-1/L1 Drugs To Market
GSK Files Blockbuster Hopeful Shingrix With FDA
Merck & Co Expands C Diff Franchise With US Zinplava Approval
GSK Shingles Vaccine Adds Evidence It Can Outperform Merck’s Zostavax
Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff
Will Portola’s Betrixaban Data Pass Muster With FDA?
Keeping Track: New Year, New Submissions Roll In To FDA


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts